• Vaccine Name: L. major DNA vaccine encoding TSA, LMSTI1, KMP11, and LACK
• Target Pathogen: Leishmania major
• Target Disease: Cutaneous leishmaniasis
• Type: DNA vaccine
• Status: Research
• Host Species for Licensed Use: Human
• KMP-11 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• TSA gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• LACK gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• LmSTI1 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001147
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: BALB/c
• Host age: 6-8 weeks old
• Host gender: Female
• Vaccination Protocol: BALB/c mice were divided into four groups (9 mice per group), one group was injected with 100 µg pleish-dom alone, one group was injected with pleish-dom combined with plasmid encoding IL-12 (50 µg+50 µg, pIL-12), another group received PBS, and one group received 100 µg empty pcDNA intramuscularly in the hind leg. The booster injections were given three times in 2-week intervals.(Salehi-Sangani et al., 2019)
• Immune Response Assay Type: Enzyme-linked immunosorbent assay (ELISA)
• Challenge Protocol: Four weeks after the last booster injection, different groups of mice were challenged subcutaneously at the base of the tail with 1×106 L. major promastigotes harvested at stationary phase. Lesion development was monitored, and the size of the lesion was recorded weekly using a Vernier caliper.(Salehi-Sangani et al., 2019)